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ABSTRACT 
The objective of this study was to control the elevated blood pressure in the patient with sudden episode of high blood pressure 
having markedly reduced function ability and restlessness. In such a case rapid onset of action is required. Prazosin Hydrochloride is 
drug with short biological half life. The purpose of study is to mask the bitter taste of drug and provide rapid onset of action. 
Inclusion complex of drug and β-Cyclodextrin can prepare by kneading method to mask the bitter taste of drug. 32 full factorial 
design was implemented, direct compression method were used to prepare tablet. F2 batch among all other batches showed 
disintegration time 55 sec with 98.56%drug release within 5min. thus it can be concluded the fast dissolving tablet can be formulated 
for antihypertensive drug. 
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INTRODUCTION 
A wide variety of pharmaceutical research is directed at 
developing new dosage forms. Most of these efforts 
have focused on either formulating novel drug delivery 
systems or increasing the patient compliance. Fast 
dissolving tablet (FDT) is the most widely preferred 
commercial products. Drug delivery through oral route 
is the most preferred and accepted way of application by 
the patients.
1
 The most popular dosage form being 
tablets and capsules, one important disadvantage of 
these dosage forms is the difficulty to swallow. 
Dysphagia is also associated with a number of medical 
conditions including stroke, Parkinson’s disease, AIDS, 
head and neck radiation therapy and other neurological 
disorders including cerebral palsy. Fast dissolving tablet 
have major advantages that is there is no need of water 
for administration, rapid onset of action, reduce risk of 
suffocation, avoid hepatic first pass metabolism.
1
The 
one of the most significant issue with FDT is the 
bitterness of the drug that can be exposed to taste bud as 
the tablet breaks apart in the oral cavity. Skillful taste 
masking technique is needed to hide this bitterness like 
formation of inclusion complex, polymer coating, resin 
complex.
2
 
Prazosin Hydrochloride is a sympatholytic drug used to 
treat high blood pressure,  It is an α1-blocker that acts as 
an inverse agonist at alpha-1 adrenergic receptors. These 
receptors are found on vascular smooth muscle, it can 
release catecholamines and hence vasoconstrictor effect 
can be minimized. The aim of the present study was to 
develop a fast dissolving tablet of Prazosin 
Hydrochloride by direct compression and to mask the 
bitter taste of Prazosin Hydrochloride. Such tablet 
should dissolve rapidly in the saliva without need of 
water and release the drug rapidly for immediate 
therapeutic effect, and be of acceptable taste.
3
 
Aher et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2018; 8(4):263-271           
ISSN: 2250-1177                                                                             [264]                                                                             CODEN (USA): JDDTAO 
MATERIAL AND METHOD 
Prazosin Hydrochloride was purchese from Swapnroop 
Drugs and Chemicals, Aurangabad. β-Cyclodextrin was 
gift sample from Glenmark  Pharmceutical,  Nashik.  All 
reagents and solvents used in the study were of 
analytical grade. 
Method 
Formation of Drug +β-Cyclodextrin Inclusion 
Complex 
Accurately weigh quantity of physical mixture of 
Prazosin Hydrochloride and β-Cyclodextrin was 
triturated in mortar and pestle with small amount of 
water. The thick slurry was kneaded until mild dryness 
(40min). The obtain dried mass was then pulverized and 
sieved through #44 
4
 
Table 1: Composition of various Inclusion 
Complexes 
S. N. Composition (Drug : β-Cyclodextrin) Ratio  
1 Prazosin Hydrochloride+β-yclodextrin 1.3 
2 Prazosin Hydrochloride+β-yclodextrin 1.5 
3 Prazosin Hydrochloride+β-yclodextrin 1.7 
 
Physical Characterization of Inclusion Complex 
Production Yield: The production yield formulation was 
calculated using the weight of final product after drying 
with respect to the initial total weight of the drug and 
carrier used for the preparation of complex. Percent 
production yields were calculated as per the formula 
mentioned below, 
   
  
  
                  Where, 
Py = Production yield, 
W0 = Practical mass (inclusion complex). 
Wt = Theoretical mass (carrier + drug).  
Drug content: 
About 5 mg drug equivalent were weighed accurately 
and transferred to 100 ml volumetric flask. From this 
stock solution (100μg/ml), 1 ml was withdrawn and 
further diluted up to 10 ml with Methanol. This solution 
was used for the assay for drug content by UV 
spectrophotometer at 246 nm. Concentration of drug in 
stock solution was calculated by using calibration curve 
and from which percentage drug content in complex was 
calculated.
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Taste Masking Evaluation method 
Spectrophotometric Method: 
Weigh accurately known amount (10mg) of taste 
masked formulation and   mixed with 10ml of distilled 
water in 10ml syringe. The syringe was revolving end to 
end five times in 30 seconds. The test medium was 
filtered through membrane filter. The absorbance was 
recorded on UV spectrophotometer at 246 nm
. 5,6
 
Fourier Transform Infrared Spectroscopy of 
Prazosin Hydrochloride: 
The infrared spectra of pure Prazosin Hydrochloride 
were taken on Bruker FTIR spectrometer. Samples were 
prepared by KBr disc method (2 mg sample in 100 mg 
KBr) and examined in the transmission mode. Each 
spectrum was measured over a frequency range of 4000–
400 cm
−1. 7-9
 
Differential Scanning Colorimetry (DSC)  
 The DSC measurements were performed on a DSC 60, 
Shimadzu, Japan differential scanning calorimeter with 
thermal analyzer. All accurately weighed samples were 
placed in a sealed aluminium pans, before heating under 
nitrogen flow (10 ml/min) at a scanning rate of 10 
0
C per 
min from 25 to 300 
0
C. An empty aluminium pan was 
used as reference.
10
 
Powder X-Ray Diffraction (P-XRD) 
For the structural, crystal, and physical state 
characterization of Prazosin Hydrochloride, X-Ray 
diffraction studies were performed for pure drug, 
Prazosin Hydrochloride and Inclusion Complex. XRD 
study was carried out with Bruker AXS D8 Advance 
with Vertical, Theta/2 geometry using copper target, a 
voltage of 40 kv and a current of 35 mA. The scanning 
was done over 2θ range of 3º to 135º. 
Method of Preparation of Powder Blend  
Inclusion complex of Prazosin Hydrochloride and other 
inactive ingredients except Sodium starch glycolate and 
Talc were mixed by using glass mortar and pestle and 
passed through sieve no. 60. The mixed material blended 
with Sodium starch glycolate and Talc. The whole 
mixture was passed through Sieve No. 60 twice. Tablets 
were prepared using 8mm round flat-faced punch of the 
rotary tablet machine [Rimek, Mini Press-1, Karnavti]. 
Compression force was constant for all formulations. 
3
2 
Full Factorial Design  
 
Table 2: Formula for Fast Dissolving Tablet of Prazosin Hydrochloride 
S.N. Ingredient F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Drug +β-CD Inclusion Complex 
equivalent to 5mg of drug 
40 40 40 40 40 40 40 40 40 
2 Sodium Starch Glycolate 2 5 8 2 5 8 2 5 8 
3 D-Mannitol 20 20 20 40 40 40 60 60 60 
4 Magnesium Stearate 3 3 3 3 3 3 3 3 3 
5 Talc 2 2 2 2 2 2 2 2 2 
6 Lactose q.s q.s q.s q.s q.s q.s q.s q.s q.s 
 Total(mg) 180 180 180 180 180 180 180 180 180 
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Evaluations of powder blend for flow properties:
13
 
Bulk Density:
 
An accurately weighed powder blend from each formula 
was lightly shaken to break any agglomerates formed 
and it was introduced in to a measuring cylinder. The 
volume occupied by the powder was measured which 
gave bulk volume. Bulk density of powder blends was 
determined using the following formula. 
Bulk density = Total weight of powder / Total volume of 
powder 
Tapped density: 
An accurately weighed powder blend from each formula 
was lightly shaken to break any agglomerates formed 
and it was introduced into a measuring cylinder. The 
measuring cylinder was tapped until no further change in 
volume was noted which gave the tapped volume. The 
tapped densities (TD) of powder blends were determined 
using the following formula. 
Tapped bulk density= Total weight of powder / Total 
volume of tapped powder 
Angle of repose: 
The frictional forces in a loose powder or granules can 
be measured by the angle of repose. This is the 
maximum angle possible between the surface of a pile of 
powder or granules and the horizontal plane.  
 tanθ = h/r θ = tan-1 (h/r)  
Where, θ is the angle of repose,  
h is the height, r is the radius. 
Hausner Ratio: 
Hausner’s ratio is an indirect index of ease of powder 
flow. 
 It is calculated by the following formula Hausner’s ratio 
= d When t is the tapped density and b is bulk density.  
Compressibility Index: 
Percent compressibility of powder mix was determined 
by Carr’s compressibility index calculated by following 
formula.  
Carr’s Index % = TBD – LBD x 100 TBD  
Where, LBD = Loose Bulk Density  
TBD = Tapped Bulk Density 
Evaluation of FDT of Prazosin Hydrochloride
 12, 13 
Thickness: 
The thickness of tablet is important for uniformity of 
tablet size. The thickness of the tablets was determined 
using a Vernier Calliper. Three tablets from each batch 
were used. 
Hardness: 
Hardness indicates the ability of a tablet to withstand 
mechanical shocks while handling. The hardness of the 
tablets was determined using Pfizer hardness tester. It is 
expressed in kg/cm
2.
  
Drug Content Uniformity Study: 
Twenty tablets were weighed individually and 
powdered. The powder equivalent to 5 mg of Prazosin 
Hydrochloride was weighed and dissolved in Phosphate 
Buffer pH 6.8. The volume was made to 100 with 
Phosphate Buffer pH 6.8. From this stock solution, 10 
µg/ml dilution of the drug was prepared. The drug 
contents of the resulting solution were calculated from 
UV absorbance at 246nm. 
Friability: 
Roche friabilator is the equipment which is used for the 
determination of friability. It is expressed in percentage. 
Note down the initial weight of the tablets individually 
(W initial). Tablets are placed in a plastic chamber 
which revolves at 25 rpm and they are subjected to fall 
from a height of 6 inches in the friabilator for about 100 
revolutions. Then measure the weight of the tablet (W 
final) and observe any weight difference before tablet 
and after the friabilator processing.  
Limits: loss in weight less than 0.5 to 1% of the initial 
weight of the tablet should be considered as acceptable 
limits. 
F= {(W initial)- (W final)/ (W initial)}×100. 
Weight Variation: 
Twenty tablets were weighed individually. Average 
weight tablet was calculated from the total weight of all 
tablets. The individual weights were compared with the 
average weight.  The  percentage  difference  in  the 
weight  variation  should  be  within  the acceptable  
limits (7.5%). The percent deviation was calculated 
using the following formula.    
% Deviation =   
                 –             
             
      
Wetting Time: 
The method was applied to measure tablet-wetting time. 
A piece of tissue paper folded twice was placed in a 
small petridish (i.d. = 6.5 cm) containing 6 ml of water, 
a tablet was put on the paper, and the time for complete 
wetting was measured. Three trials for each batch were 
performed and standard deviation was also determined 
 
Disintegration Time Study: 
The in-vitro disintegration studies were carried out using 
Tablet Disintegration Test Apparatus. One tablet was 
placed in each of the six tubes of the basket assembly 
and disk was added to each tube. This assembly was 
then suspended in one-liter beaker containing water 
maintained at 37±2
0
C. The basket was then moved up 
and down through a distance of 5 to 6 cm at a frequency 
of 28 to 32 cycles per minutes. The time required for 
complete disintegration of the tablet was recorded.  
In- vitro Drug Release Study:
 
An in-vitro drug release studies of the prepared nine 
formulations of Fast dissolving tablet were conducted 
for a period of 5 minutes using an eight station USP type 
2 apparatus (paddle type). The agitation speed was 50 
rpm. Prazosin Hydrochloride tablet were added to 900 
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ml of phosphate buffer pH 6.8 at 37 ± 0.5° C.  5 ml 
aliquots were withdrawn at time intervals of 1,2,3,4 and 
5min and filtered through Whatmans filter paper No. 41. 
An equal volume of fresh dissolution medium was 
replaced to maintain the volume of dissolution medium. 
The filtered samples were analyzed 
spectrophotometrically at 246 nm. Cumulative 
percentage of labelled amount of drug released was 
calculated. 
14
 
Dissolution Kinetics: 
Formulation of fast dissolving tablet applied various 
kinetic release model such as Zero order, First Order, 
Higuchi and Connor’s and Korsemeyer’s Peppas. Fast 
dissolving tablet of Prazosin Hydrochloride follow First 
order release kinetic, the mechanism of first order 
kinetic is Non-fickian diffusion.
 
Stability Studies:
 
The optimized formulation was wrapped in aluminum 
foil and subjected to 40 ±2°C temperature and 75±5% 
RH in oven for the period of three months. The 
formulation was analyzed for organoleptic 
characteristics, thickness, hardness, drug content, 
wetting time, disintegration time, weight variation, and 
dissolution
.15 
RESULT AND DISCUSSION 
% Drug Content and Production Yield of Inclusion 
Complex
 
Table 3: Percent Drug Content and Production Yield of Drug:β-Cyclodextrin Inclusion Complex 
Ratio of Drug:β-Cyclodextrin % Drug Content Production Yield 
1.3 97.19 84.25% 
1.5 96.15 71.10% 
1.7 98.62 90.12% 
 
Table 4: Evaluation of Taste Masking by UV Spectrophotometric method 
S. N. Absorbance of Drug Solution (246nm) Absorbance of Inclusion Complex (246) 
1 3.176 2.688 
2 3.152 2.675 
3 3.155 2.676 
 
Table 5: Result of Phase solubility study of various ratios of Inclusion Complex 
S. N. Drug Polymer Ratio Solubility 
(mg/ml) 
Fold increase 
in solubility 
1 Prazosin Hydrochloride - - 0.00221 - 
2 Prazosin Hydrochloride β –CD 1:3 0.1050 4.6 
3 Prazosin Hydrochloride β –CD 1:5 0.0450 2.1 
4 Prazosin Hydrochloride β –CD 1:7 0.1632 7.9 
 
 
 
Figure 1: FT-IR Spectrum of Pure Drug 
 
Figure 2: FT-IR Spectrum of Inclusion Complex 
(1:7)
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Table 6: FTIR Peaks of Prazosin Hydrochloride 
Observed Values 
Peaks (cm
-1
) 
Standard Values 
Peaks(cm
-1
) 
Spectrum of Prazosin 
Hydrochloride Assignment 
Pure Drug Inclusion 
Complex 
3743 >3000 =CH aromatic ring Yes Yes 
1753.54 1750-1680 C=O stretching Yes Yes 
1646 1560-1650 N-H bending Yes Yes 
1310 1000-1320 C-O stretching Yes Yes 
   
DSC Study of Prazosin Hydrochloride 
 
Figure 3: Differential Scanning Calorimetr Thermogram of pure drug Prazosin Hydrochloride 
 
 
   Figure 4: Differential Scanning Calorimetry Thermogram of Inclusion Complex         
Table 7: Interpretation of DSC Thermogram of prazosin hydrochloride 
Parameter  Drug Inclusion Complex 
Peak 279.54 210.23 
Onset 277.02 204.56 
Endset 283.22 215.38 
Heat -121.68J/g -91.45J/g 
                
P-XRD Study of Prazosin Hydrochloride 
 
Figure 5: X-Ray Diffraction of Prazosin Hydrochloride 
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Figure 6: X-Ray Diffraction of β-Cyclodextrin Inclusion Complex 
 
Table 8: Evaluation of Powder Blend 
Formulation 
Batches 
Bulk density 
(gm/ml) 
Tapped density 
(gm/ml) 
Angle of repose 
(
0
C) 
Compressibility Index 
(%) 
Hausner 
Ratio 
F1 0.40±0.090 0.436±0.021 28.79±0.60 9.51±2.79 1.12±0.053 
F2 0.391±0.017 0.466±0.015 26.57±1.37 2.24±2.13 1.04±0.021 
F3 0.384±0.022 0.454±0.040 25.97±1.97 6.55±2.03 1.11±0.11 
F4 0.366±0.025 0.444±0.025 27.14±0.61 5.48±0.18 1.10±0.041 
F5 0.382±0.015 0.487±0.035 26.34±0.66 2.46±1.26 1.10±0.094 
F6 0.373±0.027 0.468±0.021 28.34±1.14 4.65±1.16 1.02±0.081 
F7 0.396±0.017 0.450±0.014 27.03±0.99 4.81±0.19 1.11±0.069 
F8 0.385±0.017 0.474±0.018 29.48±1.19 9.41±2.51 1.09±0.025 
F9 0.394±0.015 0.498±0.017 28.26±1.05 8.92±2.36 1.07±0.061 
 
Table 9: Evaluation of Prazosin Hydrochloride Fast Dissolving Tablet 
Formulation 
batches 
Thickness (mm) 
(SD) 
Hardness (Kg/cm
2
) 
( SD) 
Drug content (%) 
( SD) 
Friability (%) 
( SD) 
F1 3.7±0.13 3.3±0.13 97.13±0.11 0.53±0.045 
F2 3.5±0.35 3.1±0.11 98.86±0.064 0.51±0.039 
F3 3.4±0.20 3.3±0.10 96±0.075 0.42±0.024 
F4 3.5±0.17 3.4±0.05 97.11±0.116 0.42±0.22 
F5 3.2±0.67 3.2±0.13 94.78±0.059 0.44±0.012 
F6 3.4±0.27 3.3±0.11 96.42±0.12 0.51±0.039 
F7 3.3±0.13 3.2±0.25 97.47±0.42 0.55±0.024 
F8 3.4±0.32 3.4±0.1 98.02±0.29 0.44± 0.012 
F9 3.4 ±0.11 3.2± 0.13 98.56±0.033 0.55± 0.020 
 
Table 10: Evaluation of Prazosin Hydrochloride Fast Dissolving Tablet 
Formulation 
batches 
Weight variation(mg) 
( SD) 
Wetting time(sec.) 
( SD) 
Water absorption 
ratio (%) 
( SD) 
Disintegration  Time 
(sec) 
( SD) 
F1 179±0.42 36.00± 1.48 54.8±0.055 84.45±0.83 
F2 178±0.55 11.00± 0.83 81.04±0.045 55.00±0.81 
F3 178±0.47 21.3±3.38 66.66±1.07 71.89±1.26 
F4 178±.041 25.8±2.77 59±0.50 75.23±1.36 
F5 178±0.39 22.00±2.34 60.16±0.88 73.00±1.72 
F6 179±.040 15.2±2.38 76.66±0.54 66.41±1.94 
F7 179±0.46 40.00±2.30 51.16±0.88 90.00±2.07 
F8 178±0.39 18.2±4.76 74.66±1.08 68.00±2.44 
F9 179±0.45 19.00±1.87 69.04±0.70 70.35±1.97 
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Table 11: Dissolution Data of Fast Dissolving Tablets of Prazosin Hydrochloride 
Formulation Batches 
% CDR 
1 min 2 min 3 min 4 min 5 min 
F1 42±2.14 53.26±2.1 70.62±1.020 79.1±2.58 85.12±2.31 
F2 52.10±1.02 64.82±0.45 77.12±2.75 86.32±1.15 98.56±2.58 
F3 46.23±2.45 57.65±2.3 73.25±2.85 82.45±1.45 91.00±2.13 
F4 43.23±2.88 55.12±2.54 72.21±0.28 80.35±2.43 86.11±2.91 
F5 48.10±2.03 54.65±1.52 73.58±2.34 81.49±2.45 90.80±2.04 
F6 50.4±0.23 61.52±1.63 75.44±0.78 84.00±1.65 95.56±1.23 
F7 41.28±1.25 52.63±0.32 68.27±1.6 76.59±2.55 82.56±1.010 
F8 49.00±2.98 60.20±1.89 75.54±2.96 83.29±2.36 94.22±2.66 
F9 47.09±1.26 59.11±2.15 74.15±0.74 81.0±2.17 92.57±2.29 
 
 
Figure 7: Dissolution profile of fast dissolving tablets of Prazosin Hydrochloride 
 
Figure 8: Model graph for comparative evaluation of first order release kinetics. 
 
Table 12: R
2 
value for various kinetic model 
Kinetic Models R
2 
Value 
First order release kinetics 0.998 
Zero order release kinetics 0.905 
Higuchi and connor’s 0.990 
Korsemeyer’s Peppas 0.895 
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Figure: 9 Surface response plot showing the effect of 
SSG and Mannitol on % Drug release of Fast 
Dissolving Tablet 
 
Figure 10: The Surface response plot showing effect 
of Sodium starch glycolate and Mannitol on 
Disintegration Time of Fast Dissolving Tablet
 
Table 13: Result of Stability Study 
Parameters 
 
Months 
0 1 2 3 
Hardness (kg/cm
2
) 3.5 3.4 3.5 3.5 
Friability (%) 0.51 0.53 0.54 0.53 
Disintegration Time(sec) 55 57 57 56 
Drug Content (%) 98.71 98.58 98.21 97.52 
% Drug release 98.56 98.59 97.87 98.12 
 
DISCUSSION 
The model drug selected (Prazosin Hydrochloride) was 
characterized and analyzed for its physical appearance 
and solubility, which complies with the monograph as 
specified in Indian pharmacopoeia and United State 
pharmacopoeia. UV and IR spectral analysis was done 
and the drug shows similar data as mentioned in 
different official publications. By FTIR analysis of pure 
Prazosin Hydrochloride showed characteristic peaks at 
3743 cm-1, 1753.54cm-1, 1646cm-1, 1310 cm-1these 
are almost same as reported in the monograph for 
Prazosin Hydrochloride (table 3)   Drug-polymer 
interaction study by FTIR for pure drug, β-Cyclodextrin 
and sodium starch glycolate showed that there were no 
significant changes in the position of the characteristic 
peaks of drug when mixed with superdisintegrants 
which indicated compatibility of polymers with the 
drug.(Figure:1 and2). DSC thermogram of untreated 
drug shows an endothermic peak at 279.54°C, which is 
related to its melting point (Figure 3). The physical 
mixture of drug and B-Cyclodextrin (Inclusion 
Complex) has endothermic peak at268.52°C (Figure 4). 
It was found that there are no new peaks appeared in the 
thermogram of the drug and excipients. Thus, there is no 
interaction between the drug and the tablet excipients, 
was observed. The XRD diffraction pattern of Prazosin 
Hydrochloride shows sharp peak indicating that the drug 
is of crystalline nature, while that of Inclusion Complex 
shows blunt peaks indicating its amorphous 
nature(Figure 5 and 6). 
The % drug content of various ratio of inclusion 
complex was found to be 96.15% - 98.62 %( table: 
3) 1:7 ratio show highest drug content (98.62%). 
Production yield of inclusion complex is ranging 
between 71.10% - 90.12 %( table 3) Taste masking 
evaluation can be done by spectrophotometric method. 
The conc. of inclusion complex is below the threshold 
conc. of drug therefore it can be concluded that the bitter 
taste of drug could be masked. (Table 4). Phase 
solubility study can be perform with various ratio of 
drug and B-Cyclodextrin (Inclusion Complex) 1:7 ratio 
show highest old solubility 7.9 fold, (table 5).  
The powder blends is subjected to precompressional 
evaluation to determine flow property have the bulk 
density of all formulation are ranged between 0.36-
0.40mg/ml (table 8 ) Tapped bulk density is  ranged 
between0.43-0.49gm/ml. (table 8) angle of repose of 
formulation  was found to be between  25-30 indicating 
excellent flow property. (Table 8) The Hausner’s ratio 
for the formulations was found to be <1.00-1.11, 
indicating excellent flow properties and indicating good 
flow property (table 8)  The carr’s index for the 
formulations was found to be below <10% indicating 
that the powders have a excellent compressibility(table 8 
)    
Thickness of Tablet formulations was found to be 
ranging from 3.2mm to 3.7 mm. Variation of thickness 
in Tablet formulations (F1 to F9) was found within the 
acceptable limits. (Table 9)  Hardness of Tablet 
formulations was found to be ranging from 3.1Kg/cm
2
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to 3.4Kg/cm
2
. (Table 9)  Percent drug content of 
Prazosin Hydrochloride for all formulation was found in 
between 98.86%. to 96.00%.(table:9)the friability value 
ranging from 0.42% to 0.55%  (table:9)  Weight 
variation for all  formulation was found to be in 178 mg 
to 179.12mg. (Table 10).  Sodium starch glycolate was 
the best superdisintegrant showing the shortest 
disintegration time. Sodium starch glycolate has 
powerful swelling capacity thus increase water 
absorption ratio and result in rapid disintegration. The 
disintegration time for formulation F1-F9 was found to 
be in the range of 55 to 90 sec. (Table 10) All 
formulation show quick wetting ranging from 11 to 
40sec. (table:10). This may be due to ability of swelling 
and also capacity of absorption of water. All 
superdisintegrants have high water absorption capacity 
water absorption ratio for all formulation was found to 
be 51.16 % to 81.04% (table 10).  % Drug releases of all 
formulation are ranging between 82.56% - 98.56% 
(table 11). F2 batch shows highest drug release. 
Formulation of fast dissolving tablet follow first order 
release kinetics that is drug released from the system 
was by Non-fickian diffusion(figure 8), R
2
 value for 
various kinetic model was showed in (table:12). 
(table:13)  showed that there was no considerable 
change in Hardness, percent friability, content 
uniformity, disintegration time, content uniformity and 
in-vitro drug release  of formulation F2 before and after 
accelerated stability study. Also formulation F2 showed 
white color after stability studies Hence FDT prepared 
was found to be stable. 
CONCLUSION 
In the present research a successful attempt was made to 
formulate fast dissolving tablets of Prazosin 
Hydrochloride by direct compression method to 
improve bitter taste of drug, bioavailability and patient 
compliance especially for the pediatric and geriatric 
patients. Prazosin Hydrochloride has poor solubility in 
water. It is a BCS Class II drug. The present study has 
shown that it is possible to increase the dissolution rate 
of poorly soluble drug Prazosin Hydrochloride by 
preparing it as Inclusion Complex with carriers like β- 
Cyclodextrin. Inclusion Complex prepared by kneading 
method in the ratio of 1:7 for drug where carrier exhibit 
rapid dissolution rate when compared with pure drug. 
Fast dissolving tablets of Prazosin Hydrochloride 
prepared by using various superdisintegrants showed 
rapid dissolution when compared with the marketed 
tablets. Based on the study, it may be concluded that 
Prazosin Hydrochloride tablets prepared by using 
Inclusion Complex with Sodium Starch Glycolate 
superdisintegrant was found to be ideal for rapid 
disintegration and for improving dissolution rate, which 
in turn increased the bioavailability. Sodium Starch 
Glycolate was the best superdisintegrant showing the 
shortest disintegration time. Sodium Starch Glycolate 
have high water absorption capacity this is necessary to 
provide the rapid disintegration in the mouth. This study 
indicates the possibility of utilizing the selected best 
formulation F2 in the preparation of Prazosin 
Hydrochloride fast dissolving tablet as a new dosage 
form for oral administration having increased solubility, 
improve bitter taste of drug, improved bioavailability, 
rapid dissolution and more patient compliance.  
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